What Labs Are Abnormal With Sjögren’s Syndrome?

Explore the various lab indicators that suggest Sjögren’s Syndrome and learn how medical professionals interpret these results.

Sjögren’s syndrome triggers a wide range of lab abnormalities, from characteristic autoantibodies like anti-Ro/SSA and anti-La/SSB to shifts in blood counts, immunoglobulin levels, and complement proteins. No single test confirms the diagnosis on its own, and many of these abnormalities do double duty: they help identify the disease and also flag which patients face a rougher course. Understanding which labs go sideways, and what those changes actually mean for you, is more layered than a simple checklist might suggest.

The Signature Autoantibodies

The two antibodies most closely tied to Sjögren’s syndrome are anti-Ro/SSA and anti-La/SSB. These are present in roughly 60 to 70 percent of people with primary Sjögren’s and are considered the hallmark serologic finding. When both are positive together, the diagnosis becomes much more likely. Anti-Ro actually comes in two subtypes, Ro52 and Ro60, and the combination of both Ro subtypes plus anti-La is the serologic pattern most strongly linked to primary Sjögren’s rather than lupus or other autoimmune conditions.

These antibodies are not just diagnostic markers. Research tracking patients before their Sjögren’s diagnosis found that anti-Ro/SSA and anti-La/SSB were already present in the blood years ahead of time and were strongly associated with early-onset disease and a more severe course. That said, about a third of people with primary Sjögren’s are seronegative for both antibodies, meaning a negative result does not rule out the disease.

Antinuclear antibodies (ANA) as a broader category are also commonly positive, alongside rheumatoid factor. A positive ANA alone is too nonspecific to mean much, but it often accompanies the more targeted antibody findings.

Rheumatoid Factor as a Prognostic Signal

Rheumatoid factor (RF) is actually the single most common autoantibody found in Sjögren’s syndrome, even more common than anti-Ro or anti-La. It is positive in about 60 percent of patients with primary Sjögren’s. Despite its name, rheumatoid factor is not specific to rheumatoid arthritis; it shows up across several autoimmune diseases and even in some healthy people.

What makes RF interesting in Sjögren’s is its role as a prognostic indicator rather than a diagnostic one. People who are RF-positive tend to have higher disease activity scores, more severe dry-eye symptoms, elevated markers of inflammation, and higher levels of circulating gammaglobulins compared to RF-negative patients. RF-positive patients also tend to have lower white blood cell counts, which signals a more active immune process. So while RF alone will not diagnose Sjögren’s, a positive result in someone already suspected of having the disease suggests they may be headed for a more complicated clinical picture.

Blood Count Changes

Sjögren’s syndrome often affects blood cell counts, though the changes tend to be mild. The most frequently seen abnormalities are mild anemia, leukopenia (low white blood cells), and thrombocytopenia (low platelets). These findings usually do not cause symptoms on their own, but they matter because they reflect the underlying immune activity and can serve as warning signs.

Leukopenia in particular deserves attention. Low white blood cell counts, especially low lymphocyte counts, are among the strongest lab-based predictors of lymphoma risk in Sjögren’s patients. One study found that lymphocytopenia carried a hazard ratio above 16 for developing non-Hodgkin lymphoma, making it one of the most powerful individual predictors identified. Low complement levels were similarly associated with dramatically elevated risk. Patients with low complement levels also had a higher proportion of leukopenia.

Immunoglobulin Levels and Hypergammaglobulinemia

One of the more telling lab abnormalities in Sjögren’s syndrome is elevated immunoglobulin G (IgG). Hypergammaglobulinemia, meaning abnormally high levels of circulating antibodies, reflects overactive B cells and is reported in roughly a third to three-quarters of patients with primary Sjögren’s, depending on the study population. This is not just a marker of immune activation; persistently high IgG levels appear to predict worse outcomes.

A three-year follow-up study found that patients whose IgG stayed consistently elevated had about twice the rate of organ damage outside the salivary and tear glands, higher symptom burden scores, and more extraglandular manifestations compared to those whose IgG stayed normal. A single elevated reading was less predictive than the persistent pattern, which is a useful distinction: your doctor tracking this over time is more informative than any one snapshot. The erythrocyte sedimentation rate (ESR) tends to run high as well, reflecting systemic inflammation, and it correlates with RF positivity and gammaglobulin levels.

Complement Proteins

Low complement levels, particularly C3 and C4, are among the lab findings that matter most in Sjögren’s syndrome because of what they signal about disease severity and lymphoma risk. Complement proteins are part of the immune system’s first line of defense, and when they are consumed by chronic immune-complex formation, their blood levels drop.

In a retrospective study of treatment-naive patients, low complement levels were independently associated with leukopenia and lymphadenopathy, and patients with both C3 and C4 depleted had significantly more anemia, fatigue, and blood-related involvement. Another study found that low C3 was linked to leukocytoclastic vasculitis and interstitial lung disease, while low C4 was similarly associated with vasculitis, lung disease, and higher disease activity and damage scores.

But the most consequential association is with lymphoma. Low C4 carried a relative-risk ratio of about 8 for non-Hodgkin lymphoma, and low C3 was associated with even higher hazard ratios in separate analyses. This is why your rheumatologist checks complement levels at regular intervals rather than just at diagnosis.

Cryoglobulins and Monoclonal Gammopathy

Cryoglobulins are abnormal immune proteins that precipitate out of the blood at cold temperatures. They are found in about 16 percent of primary Sjögren’s patients and are typically a mix of monoclonal IgM and polyclonal IgG. Their presence signals a more complicated disease state.

Monoclonal gammopathy, where a single abnormal clone of B cells produces a detectable spike on protein electrophoresis, carries similar weight. Patients with monoclonal gammopathy tend to have higher rates of swollen parotid glands, vasculitis, neurological involvement, elevated ESR, and lower complement levels compared to those without it.

Both cryoglobulins and monoclonal bands are considered red flags for lymphoma development. Rising cryoglobulin levels, persistently detectable monoclonal bands, and a pattern of declining complement activity together form a constellation that clinicians watch carefully. One study found that persistent monoclonal bands on electrophoresis carried an odds ratio of about 15 for lymphoma. A multicenter analysis identified four key biomarkers for lymphoma risk: low C4, cryoglobulins, anti-La antibodies, and leukopenia. When none of these were present in patients with salivary gland swelling, the negative predictive value for lymphoma was 98 percent.

Kidney and Electrolyte Abnormalities

Sjögren’s syndrome can quietly damage the kidneys, and the lab clues are sometimes the first hint. The most common renal problem is distal renal tubular acidosis (RTA), where the kidneys lose their ability to properly acidify urine. This leads to a characteristic set of lab findings: low potassium levels, a metabolic acidosis pattern on blood gas analysis, and alkaline urine when the blood is too acidic.

Renal involvement in Sjögren’s is underrecognized. In one prospective study, RTA was diagnosed in 29 out of 70 patients, and hypokalemic paralysis (muscle weakness or paralysis from dangerously low potassium) was the most common presentation. Patients who developed RTA tended to be younger and, interestingly, had less prominent dryness symptoms, meaning their kidney problems sometimes appeared before the classic dry eyes and dry mouth. Abnormal urinalysis results, low serum bicarbonate, or unexplained low potassium in a young person should raise the possibility of Sjögren’s even when dryness has not yet been flagged.

Liver Markers and Primary Biliary Cholangitis Overlap

Sjögren’s syndrome frequently overlaps with other autoimmune conditions, and one of the more clinically significant overlaps is with primary biliary cholangitis (PBC), a disease that attacks the small bile ducts in the liver. When PBC coexists with Sjögren’s, liver-related labs light up: elevated ALT, AST, total and direct bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) are all significantly higher than in Sjögren’s alone.

The antibodies that distinguish this overlap include anti-mitochondrial antibodies (AMA and AMA-M2) and anti-centromere antibodies (ACA). Elevated IgM levels, very high ANA titers, and a cytoplasmic staining pattern on ANA testing were all independent risk factors for having PBC alongside Sjögren’s. If your liver enzymes are persistently elevated and you have Sjögren’s, your doctor should be thinking about PBC, not just writing it off as an unrelated finding.

Antiphospholipid Antibodies

About 14 to 16 percent of people with primary Sjögren’s test positive for at least one type of antiphospholipid antibody. Full-blown antiphospholipid syndrome is uncommon, affecting only about 2 to 3 percent, but the antibodies still carry clinical weight.

Lupus anticoagulant appears to be the most relevant subtype. One study found that patients positive for lupus anticoagulant had significantly higher rates of stroke, deep vein thrombosis, and livedo reticularis, and the strokes occurred at a notably young average age of 35. The researchers recommended routine screening for these antibodies in Sjögren’s patients, paired with aggressive management of other modifiable risk factors like blood pressure and cholesterol. Antiphospholipid antibodies are not typically part of the standard Sjögren’s workup at many centers, which means they can be missed unless specifically requested.

The Lip Biopsy and What It Tells You

Not all diagnostic tests in Sjögren’s are blood-based. The minor labial salivary gland biopsy, where a small sample is taken from the inside of the lower lip, remains a cornerstone of diagnosis. Pathologists look for clusters of inflammatory cells called foci; a focus score of 1 or higher (meaning at least one cluster of 50 or more lymphocytes per 4 square millimeters) is the standard cutoff.

An elevated focus score has the highest sensitivity for Sjögren’s, found in about 82 percent of patients in one study. But additional tissue features like lymphoepithelial lesions (seen in about 68 percent), plasma cell shifts (63 percent), and germinal centers (24 percent) offer much higher specificity, reaching 98 to 100 percent. Looking at multiple features together sharpens the diagnostic accuracy considerably compared to relying on focus score alone.

Emerging and Novel Biomarkers

The traditional antibody panel misses a meaningful chunk of Sjögren’s patients, which has driven interest in newer markers. Antibodies against salivary-gland-specific proteins, including anti-SP-1, anti-CA6, and anti-PSP, appear to show up earlier than anti-Ro and anti-La and may identify a subset of patients with milder or incomplete disease who slip through conventional testing. These are not yet part of standard classification criteria, but they represent a promising direction for catching the disease sooner.

Tear and saliva cytokine profiling is another active area. Patients with primary Sjögren’s show elevated levels of multiple inflammatory mediators in their tears, including IL-8, IL-17A, interferon-gamma, and IP-10, compared to both healthy controls and people with dry eyes from other causes. In saliva, elevated IP-10 correlated with oral candida burden, and elevated MIP-1a correlated with lower salivary flow rates. These local biomarkers could eventually help distinguish Sjögren’s from ordinary dry eyes and dry mouth without requiring a biopsy, though they remain research tools for now.

For patients with lung involvement, serum KL-6 (Krebs von den Lungen-6) has emerged as a discriminating marker. A logistic regression model using KL-6 alongside disease duration identified patients with interstitial lung disease, and a combined model with KL-6 and TNF-alpha achieved strong diagnostic accuracy.

How Lab Findings Differ in Children

Sjögren’s syndrome in children does not always look the way it does in adults, and the lab picture can differ accordingly. Parotid gland swelling is often the presenting feature in kids rather than the classic dry eyes and dry mouth, and adult classification criteria fail to capture most pediatric patients. Objective dryness testing methods used in adults are not validated in children, so a clinical algorithm has been proposed that allows pediatric patients to enter diagnostic pathways through parotitis or extraglandular manifestations rather than requiring objective sicca documentation.

The practical implication is that a child with recurrent parotid swelling, even without dryness, should have their autoantibody panel checked. Relying on the same lab-plus-symptom combination that works in adults will miss many pediatric cases. Clinicians need a lower threshold for suspicion when a child presents with unexplained salivary gland inflammation or extraglandular autoimmune features like joint pain or rashes, even if the eyes and mouth seem fine.

Why Autoimmune Thyroid Labs Are Not What You Might Expect

Because Sjögren’s is an autoimmune condition, there is a common assumption that thyroid autoantibodies (anti-TPO and anti-thyroglobulin) should be elevated at higher rates than in the general population. The evidence is less clear-cut than you might think. A controlled study found anti-thyroid antibodies in about 11 percent of primary Sjögren’s patients, compared to 8 percent of healthy controls, a difference that was not statistically significant. Once patients with established autoimmune thyroiditis were excluded, the rates of thyroid antibodies were essentially the same across Sjögren’s patients, rheumatoid arthritis patients, and healthy controls. So an elevated anti-TPO in someone with Sjögren’s likely reflects coexistent thyroid disease rather than being driven by the Sjögren’s itself. It is worth screening for, but it should not be interpreted as a Sjögren’s-specific lab abnormality.